Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics publishing date : 2021 - 10 - 07 save search
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
YMAB | $14.53 -4.97% 30K
|
Health Technology
|
| O: 0.97%
H: 3.54%
C: -1.49%
disease treatment fda rare pediatric disease designation granted designation rare
Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: 0.56%
H: 2.18%
C: 1.77%
presentation molecular cancer conference
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
PRLD | $3.87 1.02% 0
|
Health Technology
|
| O: -14.52%
H: 0.0%
C: -29.51%
presentation molecular cancer conference
Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference
Published: 2021-10-07 (Crawled : 23:00) - biospace.com/
RPTX 4 | $3.3 -1.79% -1.82% 0
|
Health Technology
|
| O: -0.32%
H: 0.28%
C: -11.87%
phase 1 trial conference
Aditxt to Present at the LD Micro Main Event in Los Angeles on October 13, 2021
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
ADTX | $2.37 2.1K
|
Health Technology
|
| O: -1.91%
H: 8.31%
C: 4.55%
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
IMV | $0.8225 -2.74% 45K
|
Health Technology
|
| O: 0.93%
H: 1.84%
C: -1.84%
presentation molecular cancer liver conference
LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
LVTX | $2.74 -8.05% -7.58% 0
|
|
| O: -3.3%
H: 5.92%
C: 0.77%
treatment molecular cancer conference t-cell
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
CDTX | News | $14.57 18.55% 330K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.58%
offering
Allogene Therapeutics Reports FDA Clinical Hold of AlloCAR T Trials Based on a Single Patient Case in ALPHA2 Trial
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
ALLO | $2.93 -3.62% 160K
|
Health Technology
|
| O: 0.42%
H: 3.86%
C: 1.29%
fda trials trial clinical hold
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
BCYC | $22.67 -0.04% 0.09% 0
|
Health Technology
|
| O: -1.13%
H: 21.05%
C: 18.09%
ongoing results trial trial results
Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer
Published: 2021-10-07 (Crawled : 21:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -4.14%
H: 5.79%
C: 5.79%
SNY | News | $46.61 -2.27% -2.21% 220K
|
Health Technology
|
| O: 0.21%
H: 0.95%
C: 0.62%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -1.07%
H: 8.36%
C: 4.51%
lung cancer phase 1 cancer
CORRECTING and REPLACING: LAVA Therapeutics to Present its Bispecific Gamma Delta T Cell Engagers for Treatment of Cancer at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 18:00) - globenewswire.com
LVTX | $2.74 -8.05% -7.58% 0
|
|
| O: -3.3%
H: 5.92%
C: 0.77%
treatment molecular cancer conference t-cell
Intergalactic Therapeutics Launches with $75 Million Series A
Published: 2021-10-07 (Crawled : 17:00) - biospace.com/
CTS | News | $45.64 0.33% 0.0% 0
|
Electronic Technology
|
| O: 0.99%
H: 1.71%
C: 0.7%
therapeutics
GBT Announces New Employment Inducement Grants
Published: 2021-10-07 (Crawled : 15:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 5.12%
H: 6.14%
C: 4.12%
granted grant
Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 14:15) - globenewswire.com
RAIN | $1.21 0.0% 3.7M
|
Manufacturing
|
| O: -0.54%
H: 2.3%
C: -7.71%
molecular cancer conference
Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 13:15) - investors.phiopharma.com
PHIO | News | $0.671 -4.14% -4.17% 600
|
Health Technology
|
| O: 2.81%
H: 0.55%
C: -0.55%
molecular cancer conference
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
Published: 2021-10-07 (Crawled : 13:15) - biospace.com/
IPA | $1.22 1.6K
|
Professional, Scientific, and T...
|
| O: 0.67%
H: 13.59%
C: 3.18%
collaboration antibody research
Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degraders for the Treatment of Myc-driven Cancer
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
GLUE | $5.26 -3.84% 7.9K
|
Professional, Scientific, and T...
|
| O: 0.1%
H: 3.64%
C: -2.44%
treatment rosa potential molecular cancer preclinical pre-clinical
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors
Published: 2021-10-07 (Crawled : 13:15) - biospace.com/
OVID | $3.095 -1.75% 3K
|
Health Technology
|
| O: 0.0%
H: 5.23%
C: 4.36%
therapeutics
Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Published: 2021-10-07 (Crawled : 13:15) - globenewswire.com
MRUS | $41.97 2.82% 2.72% 0
|
Health Technology
|
| O: 45.75%
H: 2.13%
C: -5.69%
molecular cancer conference preclinical pre-clinical
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
LICN | $1.0 78.57% 3.3M
|
BOF | $1.915 63.68% 620K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.13 56.5% 500K
|
Technology Services
OPTN | $1.215 31.31% 12M
|
Health Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.